M yocardial inflammation constitutes a major component of the pathologic changes observed during cardiac allograft rejection. Prostaglandins (PGs), along with leukotrienes and lipoxins, are lipid mediators which contribute to the vasodilation, edema, and plasma protein leakage which occur during the inflammatory response. Arachidonic acid released from cellular phospholipids by phospholipase A 2 is converted by the bis-oxygenase activity of cyclooxygenase to the prostaglandin endoperoxide PGG 2 and then to PGH 2 . Prostaglandin H 2 is metabolized to biologically active products such as PGE 2 , prostacyclin, and thromboxane A 2 . 1 It is known that cyclooxygenase exists in at least 2 isoforms. 1, 2 The constitutive isoform, COX-1, is believed to be responsible for the constitutive production of PGs such as PGI 2 by endothelial cells and the gastric mucosa and thromboxane A 2 by platelets. The other isoform, COX-2, is not constitutively expressed in most tissues but can be induced in endothelial cells, fibroblasts, smooth muscle cells, and macrophages by proinflammatory cytokines, endotoxin, PGs, tumor promoters, mitogens, and hypoxia. 2, 3 It is believed that COX-2 is induced during both acute and chronic inflammatory responses and is primarily responsible for the PG synthesis that ensues. This has led to the development of drugs that selectively inhibit PG production by COX-2, avoiding the adverse consequences, such as gastric ulcers, that may result from inhibition of COX-1. 4 In different inflammatory settings, the expression of COX-2 can be deleterious or protective. 5 It has been reported that the activity of COX-1 and COX-2 can be enhanced by NO, augmenting the inflammatory response. 6, 7 Conversely, PGE 2 produced by the inducible isoform of COX can inhibit expression of inducible nitric oxide synthase (iNOS). 7 The induction of COX-2 in endothelial cells increases the synthesis of PGI 2 thereby augmenting its protective actions to inhibit platelet aggregation, promote vasodilation, and reduce monocyte adhesion and activation on endothelial surfaces. 8 In previous studies we demonstrated that during cardiac allograft rejection in rats, iNOS mRNA, protein, and enzyme activity are induced. 9 Using immunostaining, iNOS protein was demonstrated in infiltrating macrophages and lympho-cytes, endothelial cells, vascular smooth muscle cells, and cardiac myocytes within the rejecting cardiac allografts. This work was confirmed by other groups who found that iNOS is expressed in macrophages and smooth muscle cells in the vasculopathic coronary arteries of allografts undergoing chronic rejection. 10 -12 iNOS mRNA and positive immunostaining have also been demonstrated in human cardiac allografts during rejection. 13 NO produced by iNOS in this setting may impair contractile properties of the ventricle, reduce cardiomyocyte viability, and modulate the development of transplant vasculopathy. 9 -11,14,15 It may also modulate PG synthesis. 3, 6 Accordingly, the present study was designed to investigate in a rat heterotopic heart transplantation model whether COX-2 is expressed and contributes to myocardial inflammation during cardiac allograft rejection.
Methods

Cardiac Transplantation and Drug Treatment
Male Lewis (TR-11) and Wistar-Furth (WF, RT-lu) rats weighing 180 to 200 g each were purchased from Harlan Sprague-Dawley Inc (Indianapolis, Ind). Syngeneic (Lewis-Lewis) and allogeneic (LewisWistar-Furth) heterotopic abdominal cardiac transplantation was performed as previously described. 9, 16 Heart grafts in the abdomen were palpated daily. Rejection was determined by the lack of a heart beat and confirmed by inspection at laparotomy and by histological examination. Drug administration was begun on day 1 posttransplantation and continued until each assessment day (days 1, 3, and 5). 
Histology and Labeling of Apoptotic Cells
Hearts were fixed in 10% phosphate buffered formalin, embedded in paraffin, and 4 m thick sections were cut and mounted on sialine-coated slides. For routine histologic examination, sections were stained with hematoxylin and eosin to determine the extent and severity of rejection according to the International Society of Heart and Lung Transplantation classification (ISHLT). 17 Apoptotic cells were detected by in situ end-labeling, which detects the abundant DNA fragments in apoptotic nuclei using biotinylated deoxyuridine 5-triphosphate as described previously. 18, 19 Sections were also labeled for muscle actin with monoclonal antibody HHF-35 (Dako, Carpinteria, CA) using an immunoperoxidase technique which stained the cytoplasm of cardiac myocytes brown. The same immunoperoxidase technique was used to characterize the inflammatory infiltrate by labeling for T cell markers (anti-CD3) and macrophages (ED1). 
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COX-2 Immunohistochemistry
The RR6 monoclonal anti-mouse-COX-2 antibody was obtained from Dr Peter Isakson (G.D. Searle/Montsanto Co., St. Louis, Mo). 20 The monoclonal anti-rat COX-1 antibody was obtained from Accurate Chemical Co (Westbury, NY). Immunohistochemistry was performed as previously described. 20 Sections were then incubated with the anti-COX-2 Ab (clone RR6) diluted 1:150 in 5% horse serum PBS overnight at 4°C. Binding of the primary Ab to COX-2 was detected with the avidin-biotin-peroxidase technique labeling the site of the target antigen (COX-2) brown. For the COX-1, the primary antibody was diluted with 3% horse serum in PBS up to 1:150 and incubated at 4°C overnight. Horse anti-mouse secondary antibody was diluted 1:200 (Vector Laboratories, Burlingame, CA) and incubated for 30 minutes. Normal mouse serum was used as a negative control.
COX-2 and iNOS mRNA Ribonuclease Protection Assay
Specific mRNAs for COX-2 and iNOS were quantified by ribonuclease protection assay (RPA). Assay reagents and the procedures used were from an Ambion RPAII™ kit (Ambion Inc, Austin, Tex). The plasmid DNA used as a template for the rat iNOS probe was generously provided by Charles Rodi, Searle/Montsanto, St. Louis, Mo. For the COX-2 RPAs, frozen graft or native hearts were thawed in guanidine isothiocyanate. Total RNA was isolated using the Ambion To-Tally™ RNA kit. Samples of total RNA were hybridized, digested, and separated. After electrophoresis, the gel was fixed and dried. Band intensities were quantified by electronic autoradiography using a Packard Instant Imager. The plasmid DNA used as a template for the rat COX-2 probe was graciously provided by P. Worley, Johns Hopkins School of Medicine, Baltimore, Md.
COX-2 Enzyme Protein Assay
The excised hearts were rinsed and flushed via the aorta with ice-cold saline to completely remove blood, then immediately frozen at Ϫ70°C. The frozen ventricular tissue was homogenized at 4°C in RIPA-lysis buffer supplemented with 10 g/mL antipain, leupeptin and trypsin-inhibitor, and 0.1 mg/mL phenylmethylsulfonyl fluoride. Homogenates were centrifuged at 16 000g for 30 minutes at 4°C. The protein concentration of supernatants were determined by BCA protein assay (Pierce) with BSA as standard. The total protein equivalents (40 g per lane) for each sample were separated by 8% SDS-PAGE and electrotransferred to nitrocellulose membrane. After blocking nonspecific binding with TBS buffer containing 8% nonfat dried milk and 2% BSA, the membranes were immunoblotted with a mouse COX-2-specific (clone RR6) monoclonal antibody at a dilution of 1:2000 (Ͼ1000-fold selectivity for mouse COX-2 compared with mouse COX-1 21 ). The blots were subsequently incubated with a horseradish peroxidase-conjugated secondary antibody and detected by the enhanced chemiluminescence method (DuPont NEM). The level of COX-2 protein was quantified using densitometric analysis (NIH image 1.60 software).
iNOS Enzyme Protein and Activity Assay iNOS enzyme protein was measured as described above for the COX-2 protein assay. The anti-mouse iNOS polyclonal antiserum was a gift from Dr Mark Currie, G.D. Searle/Montsanto Co. iNOS enzyme activity was measured as previously described. 9, 18 Prostaglandin Assay Both transplanted and native hearts were removed, cut into 2 slices, and immediately immersed in a HEPES-buffered Krebs solution. One slice was incubated in oxygenated Krebs solution only, the other was incubated in oxygenated Krebs solution containing bradykinin (100 M) at 37°C, for 30 minutes. The supernatant was collected, mixed with water and methanol (10%), centrifuged at 4°C for 15 
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minutes at 375g and loaded on a C18 cartridge (Millipore, Bedford, MA). This was followed by serial washings with deionized water, 10% methanol, petroleum ethyl, and elution with redistilled ethyl acetate, followed by evaporation of the organic phase under nitrogen. After suspending the pellets in phosphate buffer, prostaglandin E 2 in the samples was measured with the TiterZyme PGE 2 kit (PerSeptive Biosystems, Framingham, Mass).
Statistical Analysis
The time course of changes in COX-2 mRNA and protein and iNOS mRNA levels and enzyme activity were analyzed by ANOVA. PGE 2 values were analyzed by ANOVA after log transformation due to the markedly nonnormal distribution of the values. The degree of apoptosis at each of the time points was analyzed using the nonparametric Kruskal-Wallis procedure. Survival rates were compared using the Mann-Whitney test.
Results
The expression of COX-2 mRNA was significantly increased in the rejecting cardiac allografts in comparison to syngeneic grafts on days 3 to 5 following transplantation (Figure 1 ). The COX-2 protein was also significantly upregulated in the rejecting allografts on days 4 to 5 posttransplantation ( Figure  2 ). COX-1 mRNA was also increased in rejecting allografts on days 3 to 5 ( Figure 3 ). To assess PG production in the rejecting graft tissue, myocardial slices from day 5 cardiac allografts and from the native hearts of the same rats were incubated in oxygenated buffer alone and in oxygenated buffer containing bradykinin (100 mol/L). The mean PGE 2 concentration per milligrams protein in the incubation media was significantly higher (PϽ0.05) in rejecting allografts in comparison to nonrejecting native hearts under control conditions, 474Ϯ678 versus 135Ϯ156 pg/mg of tissue and after bradykinin treatment, 1434Ϯ2451 versus 321Ϯ309 pg/mg of tissue (nϭ10). Positive immunostaining for COX-2 was not observed in native hearts and syngeneic hearts other than a slight staining of rare endothelial cells ( Figure 4C ). COX-2 immunostaining in rejecting allografts was markedly increased in macrophages, damaged cardiomyocytes and in endothelial cells and smooth muscle cells especially in myocardial regions with an inflammatory infiltrate ( Figure 4D ). The increased expression of COX-2 mRNA (Figure 1 ) was similar in time and extent to the expression of iNOS mRNA in the allografts ( Figure 5 ). Positive immunostaining for COX-1 was apparent in endothelial and endocardial cells of the native hearts ( Figure 4A) . In rejecting allografts, COX-1 immunostaining was increased in endothelial cells. It was not observed in macrophages but was present in damaged cardiomyocytes ( Figure 4B) .
Treatment of the allograft recipients with L-NIL had no significant effect on COX-2 protein levels in the rejecting allografts but was associated with a reduction in iNOS enzyme activity (Figures 6B and 7) . Treatment with the combination of SC-58125 and L-NIL was associated with a reduction of COX-2 protein in the 5-day rejecting allografts of 10% to 15% ( Figure 6B) . Survival of the cardiac allografts treated with the 2 inhibitors was increased slightly but significantly from 5.4Ϯ0.5 to 6.4Ϯ0.5 days (nϭ8, PϽ0.05). However, both the allografts treated with vehicle and the allografts treated with the inhibitors (Figure 8) showed severe inflammation and multiple foci of myocyte damage at day 5. In the SC-58125 plus L-NIL-treated animals, COX-2 immunostaining was most apparent in the infiltrating macrophages, with decreased immunostaining of cardiac myocytes ( Figure  9 ). In both treated and untreated cardiac allografts, the number of apoptotic cardiac myocytes and the total number of apoptotic nuclei increased exponentially during rejection ( Figure 10 ). There was no significant difference in the mean numbers of apoptotic nuclei in treated (nϭ6) versus untreated (nϭ3) allografts (16.1Ϯ9.6 versus 7.5Ϯ4.5) at day 5. Similarly, there was no significant reduction in the rejection grade of the treated cardiac allografts (Table) .
Discussion
The data in this study indicate that during cardiac allograft rejection COX-2 mRNA and protein are upregulated significantly in the rejecting allografts at days 3 to 5 following transplantation, in comparison to the levels observed in syngeneic grafts at the same time points. Prostaglandin synthesis was also significantly higher in myocardial tissue from the rejecting allografts 5 days after transplantation in comparison to that observed in native hearts. Immunostaining indicated that COX-2 protein was markedly expressed in endothelial cells, vascular smooth muscle cells, macrophages infiltrating the myocardium, and focally in cardiac myocytes that appeared damaged. The upregulation of COX-2 during cardiac allograft rejection in this rat model paralleled in time and extent the upregulation of iNOS mRNA, protein, and enzyme activity. 9,18 COX-1 protein was also significantly increased at days 3 to 5, probably due to increased expression of COX-1 in endothelial cells.
The expression of COX-2 together with that of iNOS has previously been noted in a model of ureteral obstruction in rats which leads to hydronephrosis and renal inflammation, 22 in rat adjuvant arthritis, 21 in carrageenin-induced pleurisy, 23 in a model of subcutaneous inflammation produced by air injection 24, 25 in human osteoarthritis-affected cartilage, 26 and in rat hearts following treatment with lipopolysaccharide. 27 The co-induction of COX-2 and iNOS has also been observed in studies in vitro of rat vascular smooth muscle cells, 28, 29 glomerular mesangial cells, 7 murine macrophages, 30 rat islets of Langerhans, 31 human endothelial cells, 32 articular chondrocytes, 33 and rabbit hepatocytes 34 incubated with endotoxin and/or cytokines but not in similar studies of human fetal cell fibroblasts 6 or bovine aortic endothelial cells. 35 Proinflammatory cytokines known to be synthesized and released by T lymphocytes and macrophages during cardiac allograft rejection are probably responsible for induction of COX-2 in this situation. 36 In studies of porcine endothelial cells, exposed to xenoreactive antibodies and complement, IL-1␤ mediated the upregulation of COX-2 and synthesis of PGE 2 and TXA 2 . 37 In studies of neonatal ventricular myocytes, IL-1␤ induced iNOS, COX-2 mRNA, and protein along with a 200-fold increase in PGE 2 . 38 The relationship between the cyclooxygenase and NO pathways varies depending on the circumstances. In cultured bovine endothelial cells, NO or NO donor drugs have been shown to inhibit PGI 2 release by bradykinin (COX-1) 39 and to inhibit COX-2 induction and activity in rat Kupffer cells. 34 In contrast, however, NO and NO donor drugs have been shown to stimulate COX-1 and COX-2 activity in endotoxin-activated murine macrophages 6 and in vascular smooth muscle cells 28 and human endothelial cells. 39, 40 Similarly, in the hydronephrotic model of renal inflammation, 22 in air-pouchinduced inflammation, 24 there is evidence that NO augments the activity of COX-1 and COX-2, leading to enhanced synthesis of prostaglandins. The mechanism responsible for the effect of NO on COX activity is unclear but may involve nitrosylation of a cysteine residue in the active site of the COX enzymes, 41 leading to the formation of nitrosothiols; these can produce structural changes in the enzyme, leading to increased COX catalytic efficiency. 42 In other studies, it was demonstrated that NO enhanced the IL-1␤-induced expression of the COX-2 mRNA and protein. 43 The cytokine and endotoxin upregulation of COX-2 and iNOS in various cells and tissues is suppressed by dexamethazone and by other immunosuppressive drugs such as cyclosporin A and FK506. 4, 10, 22, 25, 44 As mentioned previously, endothelial cell expression of COX-2 may be vasculoprotective by augmenting PGI 2 synthesis. 8 The finding of increased myocardial fibrosis in COX-2 knockout mice suggests that endocardial endothelial cell COX-2 may also be protective by augmenting PGI 2 production. 45 In the present study, potent selective inhibitors of COX-2 and of iNOS were administered to rats undergoing cardiac transplantation. 21, 46 The administration of SC-58125 together with L-NIL resulted in the downregulation of the expression of COX-2 protein in the treated allografts, a finding that has been reported previously using an arthritis model in rats. 21 The explanation for this is unclear but may reflect a role for PGs in the enhancement of COX-2 expression. The administration of L-NIL was associated with a marked reduction of iNOS enzyme activity in the rejecting allografts. However, there was only a slight increase in the survival of the cardiac allografts treated with both inhibitors.
In previous studies using cardiac allograft experimental models in rats, the expression of iNOS in the rejecting allografts was associated with increased myocardial inflammation. In the studies of Worrel et al, 10, 44 animals treated with aminoguanidine, a potent iNOS inhibitor (which also has antioxidant and other effects), was associated with a reduction in the intensity of the pathological changes of rejection in Figure 10 . Cardiac allografts 5 days posttransplantation from a vehicle-treated (a) and SC-58125-and L-NIL-treated (b) rat labeled for apoptotic nuclei (blue) and cardiac myocytes (brown). The number of apoptotic cardiac myocytes (arrow) increased exponentially in allografts from both treated and untreated animals. Many apoptotic nuclei are also found within the inflammatory infiltrate. Magnification ϫ400. Grades (0 -6) correspond to the ISHLT classification. February 1, 2000 the cardiac allografts. In a report from Koglin et al 47 and in unpublished experiments in our laboratory, there was also reduced myocardial inflammation in cardiac allografts transplanted into iNOS-deficient mice in comparison to that seen in wild type control recipients. In the present study, there were slight but not significant reductions in the myocardial inflammation in the animals treated with the selective COX-2 and iNOS inhibitor drugs. Modest reductions in the degree of inflammation and the magnitude of the inflammatory infiltrate have also been reported following administration of SC-58125 to rats with adjuvant arthritis 21 and to rats with carrageenin-induced pleurisy. 23 Apoptosis of cardiac myocytes and of infiltrating macrophages has also been observed in parallel with the upregulation of iNOS mRNA, protein, and enzyme activity in rejecting rat cardiac allografts and in human endomyocardial biopsies from hearts undergoing class 3 (ISHLT) rejection. 18, 48 These associations, along with in vitro studies of NO-mediated cardiomyocyte apoptosis, have suggested that NO may be an apoptotic trigger in this situation. 49, 50 The slight reductions observed in apoptotic cell numbers in the animals treated with the COX-2 and iNOS inhibitors were not statistically significant. Recently, however, Koglin et al reported that during cardiac allograft rejection in iNOS knockout mice, the number of apoptotic cells was significantly reduced. 47 It is of interest that von Knethen and Brune, in studies of NO-mediated apoptosis of RAW 264.7 macrophages in vitro, developed strong evidence that COX-2 is an essential regulator of apoptosis. 51 In summary, COX-2 mRNA and enzyme protein are upregulated in parallel with iNOS during cardiac allograft rejection. Although in this experimental model allograft survival was prolonged slightly, myocardial inflammation and cardiomyocyte apoptosis were not significantly reduced by treatment with a combination of inhibitors of COX-2 and iNOS.
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